AM2233 |
| Katalog-Nr.GC40601 |
AM2233 is a full agonist of the central cannabinoid (CB1) receptor (Ki = 2.8 nM).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 444912-75-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
AM2233 is a full agonist of the central cannabinoid (CB1) receptor (Ki = 2.8 nM). Most of the affinity towards the CB1 receptor resides within the (R)-enantiomer of AM2233, which exhibits a Ki value of 0.2 nM and has ~8-fold higher affinity for CB1 compared to WIN 55,212-2 (Ki = 1.6 nM). AM2233 was developed for use as a selective radioligand for mapping the distribution of the CB1 receptor in the brain. Recently, however, AM2233 has received attention as a cannabimimetic acquired for recreational use as a "legal high" replacement for restricted substances. This compound is intended for forensic and research applications.
Average Rating: 5 (Based on Reviews and 7 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *